MedPath

Heparin 100U/L for Prevention of PVC Complications

Phase 3
Completed
Conditions
Peripheral Venous Catheter Complications
Occlusion
Ecchymosis
Phlebitis
Registration Number
NCT01131754
Lead Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Brief Summary

Flushes with saline solution are used for maintaining patency of peripheral intermittent intravenous catheters in many institution based on the results of previous studies showing that 10 U heparin/mL is not better than saline in this respect. The latest meta-analysis investigated also safety and efficacy of heparin concentrations of 100 U/ml used as an intermittent flush, but no firm conclusion was reached because of limitations of the few available studies.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
214
Inclusion Criteria
  • requiring i.v. therapy for an expected duration longer than five days
  • admitted to the 3rd medical ward of IRCCS Policlinico San Matteo
Exclusion Criteria
  • bleeding tendency
  • platelet count less than 100 x 109/L
  • coagulation defects
  • previous adverse reaction to heparin
  • programmed cytotoxic therapy
  • inability to give an informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Phlebitis or Occlusion

Phlebitis is defined as the presence of two or more symptoms/signs among pain, tenderness, warmth, erythema, swelling, or a palpable cord (score of ≥ 2 according to the Visual Infusion Phlebitis Score). Occlusion is defined as resistance to flushing as evidenced by the inability to administer 1 ml of flushing solution within 30 seconds.

Secondary Outcome Measures
NameTimeMethod
Ecchymosis

Ecchymosis is defined as a purple discoloration of the skin around the catheter insertion site larger than 1 cm.

Heparin induced thrombocytopenia

Heparin induced thrombocytopenia is defined as a fall in platelet count \> 50% of baseline value without any alternative explanation. To detect this phenomenon, platelet count is to be performed at baseline and, subsequently, every 5 days.

Trial Locations

Locations (1)

Medicina 3 - IRCCS Policlinico San Matteo

🇮🇹

Pavia, Italy

Medicina 3 - IRCCS Policlinico San Matteo
🇮🇹Pavia, Italy

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.